NLA Session Highlights
National Lipid Association’s 2017 Scientific Sessions Highlights- Interview with the Experts
Speakers: Peter H. Jones, MD, FACP, FNLA, Associate Professor of Medicine
Christie M. Ballantyne, MD, FNLA, Professor of Medicine
Duration: 60 minutes
Presented on: August 9, 2017
Peter H. Jones, MD, FACP, FNLA
Peter H. Jones, MD, FACP, FNLA
Associate Professor of MedicinePeter Howard Jones, MD, FACP, FNLA, is an associate professor in the Department of Medicine, Center for Cardiovascular Disease Prevention at the Baylor College of Medicine in Houston, Texas. He also serves as co-director of the Lipid Metabolism and Atherosclerosis Clinic, and is the medical director for the Weight Management Center at the Houston Methodist Hospital. Dr Jones has served on numerous academic, scientific and community committees, and has published more than 200 clinical abstracts, articles, and chapters in textbooks. He is the chief science officer for the National Lipid Association and an associate editor of the Journal of Clinical Lipidology. Dr Jones received his medical degree from Baylor College of Medicine, where he also completed his internal medicine residency.
Christie M. Ballantyne, MD, FNLA
Christie M. Ballantyne, MD, FNLA
Professor of MedicineChristie Ballantyne, MD, is director for the Center for Cardiovascular Disease Prevention at the Houston Methodist DeBakey Heart & Vascular Center in Texas, as well as vice chair of research for the Department of Medicine, chief of cardiology, and chief of cardiovascular research at Baylor College of Medicine. He is an investigator for the American Heart Association and he receives funding from the National Institutes of Health in basic research of leukocyte-endothelial interactions, translations research in biomarkers and clinical trials. Dr Ballantyne has over 600 publications in the area of atherosclerosis, lipids and inflammation, is an editorial director for www.lipidsonline.org, and is on the editorial board for Circulation. He received is MD from Baylor College of Medicine.
ACCREDITATION INFORMATION ACTIVITY TITLE National Lipid Association's 2017 Scientific Sessions Highlights– Interview with the ExpertsACTIVITY FORMAT Internet Enduring Material •Release Date: August 10, 2017 •Expiration Date: August 10, 2018 ACTIVITY FEE: There is no fee for this activity.
TARGET AUDIENCE This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.
TYPE OF ACTIVITY Knowledge
EDUCATIONAL OBJECTIVES At the conclusion of this activity, all participants should be able to:
- Review the role of genetic testing and gene risk scores in lipid disorders;
- Explain Familial Chylomicronemia Syndrome;
- Assess the implications of ongoing lipid treatment outcomes trials for the future clinical management of patients with dyslipidemia;
- Discuss strategies to improve knowledge, skills or performance of the health care team.
CRITERIA FOR SUCCESS To participate in the activity, go to http://www.cardiocarelive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the posttest. If you have questions about this CME/CE activity, please contact the NLA at firstname.lastname@example.org. Please claim credit by August 10, 2018.
COMMERCIAL SUPPORT This activity is supported by educational funding provided by Akcea Therapeutics, A Subsidiary of Ionis Pharmaceuticals, Inc., Amgen, and Kowa Pharmaceuticals America, Inc.
Credit provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and PlatformQ Health Education, LLC. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation Statement The National Lipid Association designates this enduring internet activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
Physician Assistants NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
Pharmacists Universal Activity Number 0624-9999-17-044-H01-P (Knowledge) This Activity has been approved for 1.00 contact hour(s) (.1 CEUs) of the Accreditation Council for Pharmacy Education
Nursing The maximum number of hours awarded for this CE activity is .9 contact hours.
FACULTY PROGRAM CHAIR Peter H. Jones, MD, FACP, FNLA Associate Professor of Medicine Co-director, Lipid Metabolism and Atherosclerosis Clinic Center for Cardiovascular Disease Prevention Houston Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, TX Diplomate, American Board of Clinical Lipidology FEATURED FACULTY Christie M. Ballantyne, MD, FNLA Professor of Medicine Chief, Section of Cardiovascular Research Director, Center for Cardiovascular Disease Prevention Baylor College of Medicine Houston, TX Diplomate, American Board of Clinical Lipidology FACULTY/PLANNER/STAFF FINANCIAL DISCLOSURES FACULTY/PLANNER FINANCIAL DISCLOSURES Name Relationship Company Consultant Abbott Laboratories, Amarin Corp., Amgen, AstraZeneca, Eli Lilly and Company, Esperion Therapeutics, Inc., Genzyme, Ionis, Matinas BioPharma Holdings, Inc., Merck & Co., Inc., Novartis, Pfizer, Regeneron, Roche Diagnostics, Sanofi- Synthelabo, Inc. Ballantyne, Christie Contracted Research Abbott Laboratories, Amarin Corp., Amgen, Inc., Eli Lilly And Company, Esperion Therapeutics, Inc., Novartis AG, Otsuka America Pharmaceutical, Pfizer, Regeneron, Roche Diagnostics, sanofi- aventis, Takeda Pharmaceuticals Consultant Amgen, Merck & Co., Inc., sanofi-aventis U.S., and Regeneron Pharmaceuticals; Jones, Peter Contracted Research Abbott Laboratories, Amarin Corp., Amgen, Inc., Eli Lilly And Company, Esperion Therapeutics, Inc., Novartis AG, Otsuka America Pharmaceutical, Pfizer, Regeneron, Roche Diagnostics, sanofi- aventis, Takeda Pharmaceuticals STAFF DISCLOSURES PlatformQ Health Education, LLC N/A Nothing to Disclose NLA N/A Nothing to Disclose NLA CME REVIEWERS Hemphill, Linda Consultant Contracted Research Amgen, Regeneron IONIS, Regeneron/Sanofi
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLOSURE DECLARATION It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
DISCLAIMER This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader's misunderstanding of content.
ESTIMATED TIME TO COMPLETE This activity consists of one session, which should take approximately 60 minutes to complete.
HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
CONTACT INFORMATIONAccreditation Support: Please contact the National Lipid Association at email@example.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com.